Akero Therapeutics, Inc.
|Number of Estimates|
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Market Cap: 606 Million
Primary Exchange: NASDAQ
Shares Outstanding: 28.6 Million
Float: 10.9 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 167 trading days
From: 2019-08-28 To: 2020-03-31
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|